Maragh Samantha, Jakupciak John P, Wagner Paul D, Rom William N, Sidransky David, Srivastava Sudhir, O'Connell Catherine D
Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA.
BMC Med Genet. 2008 Feb 7;9:7. doi: 10.1186/1471-2350-9-7.
Whole genome amplification (WGA) methods allow diagnostic laboratories to overcome the common problem of insufficient DNA in patient specimens. Further, body fluid samples useful for cancer early detection are often difficult to amplify with traditional PCR methods. In this first application of WGA on the entire human mitochondrial genome, we compared the accuracy of mitochondrial DNA (mtDNA) sequence analysis after WGA to that performed without genome amplification. We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence.
DNA was isolated from clinical samples and sent to NIST. Samples were amplified by PCR and those with no visible amplification were re-amplified using the Multiple Displacement Amplificaiton technique of whole genome amplification. All samples were analyzed by mitochip for mitochondrial DNA sequence to compare sequence concordance of the WGA samples with respect to native DNA. Real-Time PCR analysis was conducted to determine the level of WGA amplification for both nuclear and mtDNA.
In total, 19 samples were compared and the concordance rate between WGA and native mtDNA sequences was 99.995%. All of the cancer associated mutations in the native mtDNA were detected in the WGA amplified material and heteroplasmies in the native mtDNA were detected with high fidelity in the WGA material. In addition to the native mtDNA sequence present in the sample, 13 new heteroplasmies were detected in the WGA material.
Genetic screening of mtDNA amplified by WGA is applicable for the detection of cancer associated mutations. Our results show the feasibility of this method for: 1) increasing the amount of DNA available for analysis, 2) recovering the identical mtDNA sequence, 3) accurately detecting mtDNA point mutations associated with cancer.
全基因组扩增(WGA)方法使诊断实验室能够克服患者样本中DNA不足这一常见问题。此外,对癌症早期检测有用的体液样本通常难以用传统PCR方法进行扩增。在WGA首次应用于整个人类线粒体基因组的过程中,我们将WGA后线粒体DNA(mtDNA)序列分析的准确性与未进行基因组扩增时的序列分析准确性进行了比较。我们将该方法应用于一小群癌症病例和对照,结果表明WGA能够增加具有相同基因序列的起始DNA材料的产量。
从临床样本中分离DNA并送至美国国家标准与技术研究院(NIST)。样本通过PCR进行扩增,对于无可见扩增的样本,使用全基因组扩增的多重置换扩增技术进行重新扩增。所有样本均通过线粒体芯片分析线粒体DNA序列,以比较WGA样本与天然DNA的序列一致性。进行实时PCR分析以确定核DNA和mtDNA的WGA扩增水平。
总共比较了19个样本,WGA与天然mtDNA序列之间的一致性率为99.995%。天然mtDNA中所有与癌症相关的突变均在WGA扩增材料中被检测到,并且天然mtDNA中的异质性在WGA材料中被高度保真地检测到。除了样本中存在的天然mtDNA序列外,在WGA材料中还检测到13个新的异质性。
对经WGA扩增的mtDNA进行基因筛查适用于检测癌症相关突变。我们的结果表明该方法具有以下可行性:1)增加可用于分析的DNA量;2)恢复相同的mtDNA序列;3)准确检测与癌症相关的mtDNA点突变。